SAVANNAH is a global, randomized, single-arm phase II trial that is studying the efficacy of savolitinib with osimertinib in patients with EGFR-mutant, locally advanced or metastatic NSCLC with MET overexpression and/or amplification, who progressed following treatment with osmiertinib. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.